Eric Easom - 10 Nov 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Eric Easom
Issuer symbol
ANTX
Transactions as of
10 Nov 2022
Net transactions value
-$67,974
Form type
4
Filing time
14 Nov 2022, 19:48:04 UTC
Previous filing
09 Nov 2022
Next filing
24 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Sale $67,628 -4,413 -47% $15.32 4,930 10 Nov 2022 Direct F1, F2
transaction ANTX Common Stock Sale $346 -23 -0.47% $15.04 4,907 14 Nov 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Price reported is a weighted-average sales price. The shares were sold at prices ranging from $15.00 to $15.85. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.